New GLP-1 Clinical Study Finds Calocurb® Reduces Body Weight and Body Fat Without Loss of Muscle Mass
Calocurb, the New Zealand-based company bringing the world the first 100% natural GLP-1 activator, announces today the publication of a new clinical study in US medical journal, Obesity Pillars, demonstrating Calocurb’s effectiveness in weight loss and muscle preservation. In the brand’s fourth human clinical study users saw an average weight loss of 8.3 lbs (3.77 kg) after six months of consistent use paired with ‘real world’ healthy diet and exercise advice. There was no loss in muscle mass.
